{"filing":{"accession_number":"0001829126-26-009659","cik":"0001527352","ticker":"NXL","company_name":"Nexalin Technology, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-28","primary_document":"nexalintec_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1527352/000182912626009659/nexalintec_8k.htm"},"events":[{"id":31367,"run_id":28776,"accession_number":"0001829126-26-009659","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Carolyn Shelton's departure from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs on August 28, 2026 is the principal disclosed action. While the separation agreement includes compensatory elements (one month base salary, $20,000 bonus, accelerated vesting, health insurance subsidy), the core event is the executive's departure from a senior officer position. The disclosure centers on the fact and terms of her leaving, making exec_departure the most salient classification.","company_name":"Nexalin Technology, Inc.","ticker":"NXL","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34220,"accession_number":"0001829126-26-009659","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Carolyn Shelton's departure from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs on August 28, 2026 is the principal disclosed action. While the separation agreement includes compensatory elements (one month base salary, $20,000 bonus, accelerated vesting, health insurance subsidy), the core event is the executive's departure from a senior officer position. The disclosure centers on the fact and terms of her leaving, making exec_departure the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:51:55.424490+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34220,"accession_number":"0001829126-26-009659","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Carolyn Shelton's departure from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs on August 28, 2026 is the principal disclosed action. While the separation agreement includes compensatory elements (one month base salary, $20,000 bonus, accelerated vesting, health insurance subsidy), the core event is the executive's departure from a senior officer position. The disclosure centers on the fact and terms of her leaving, making exec_departure the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:51:55.424490+00:00","company_name":"Nexalin Technology, Inc.","ticker":"NXL","filing_date":"2026-09-02"}]}